Patents by Inventor Luiz Belardinelli

Luiz Belardinelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of decreasing hepatotoxic side effects using Aadenosine receptor antagonists
    Patent number: 8188099
    Abstract: The invention is related to a method of decreasing hepatotoxic side effects using an A2B adenosine receptor antagonist and utility in the treatment of liver damage caused by undergoing hepatotoxic treatment, such as chemotherapy or radiation. The invention also relates to pharmaceutical compositions for use in the method.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: May 29, 2012
    Assignee: Gilead Sciences, Inc.
    Inventors: Luiz Belardinelli, Dewan Zeng, Hongyan Zhong
  • Myocardial perfusion imaging method
    Patent number: 8183226
    Abstract: The present disclosure provides 2-adenosine N-pyrazole compounds exemplified by the structure shown below that are potent and selective agonists for A2A adenosine receptor, compositions comprising these compounds, and methods for using these compounds in a variety of applications including myocardial perfusion imaging and coronary vasodilation methods.
    Type: Grant
    Filed: January 27, 2010
    Date of Patent: May 22, 2012
    Assignee: Gilead Sciences, Inc.
    Inventor: Luiz Belardinelli
  • Myocardial perfusion imaging methods and compositions
    Patent number: 8133879
    Abstract: The present disclosure provides 2-adenosine N-pyrazole compounds of structural formula shown below that are potent and selective agonists for A2A adenosine receptor, compositions comprising these compounds, and methods for using these compounds in a variety of applications including myocardial perfusion imaging methods.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: March 13, 2012
    Assignee: Gilead Sciences, Inc.
    Inventors: Luiz Belardinelli, Mitchell Rosner
  • METHOD OF TREATING ARRHYTHMIAS
    Publication number: 20120046299
    Abstract: Methods are provided for treating arrhythmias including tachycardias, such as idiopathic ventricular tachycardia, ventricular fibrillation, and Torsade de Pointes (TdP) in a manner that minimizes undesirable side effects.
    Type: Application
    Filed: July 25, 2011
    Publication date: February 23, 2012
    Inventors: Luiz Belardinelli, Charles Antzelevitch, Brent Blackburn
  • Use of Aadenosine receptor agonists
    Patent number: 8106029
    Abstract: Myocardial imaging methods are provided that are accomplished by administering doses of a pharmaceutical composition comprising one or more adenosine A2A receptor agonists, in particular regadenoson, useful for, among other indications, myocardial imaging and coronary vasodilation, in an amount sufficient to achieve at least a minimal increase in average coronary peak flow velocity.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: January 31, 2012
    Assignee: Gilead Sciences, Inc.
    Inventors: Toufigh Gordi, Ann Walls Olmsted, Hsiao Dee Lieu, Luiz Belardinelli
  • Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension
    Publication number: 20120003329
    Abstract: This disclosure relates generally to treating patients having pulmonary hypertension, or symptoms associated therewith, by administering a therapeutically effective amount of an A2B receptor antagonist to the patient.
    Type: Application
    Filed: June 29, 2011
    Publication date: January 5, 2012
    Inventors: Luiz Belardinelli, Dewan Zeng, Hongyan Zhong
  • USE OF RANOLAZINE FOR TREATING PULMONARY HYPERTENSION
    Publication number: 20120004188
    Abstract: This disclosure relates generally to treating patients having pulmonary hypertension such as pulmonary arterial hypertension (PAH), or symptoms associated therewith, by administering a therapeutically effective amount of ranolazine or a salt or salts thereof to the patient.
    Type: Application
    Filed: June 14, 2011
    Publication date: January 5, 2012
    Inventor: Luiz Belardinelli
  • Methods of coronary imaging
    Patent number: 8071566
    Abstract: The present invention provides methods of myocardial perfusion imaging and increasing coronary blood flow of a mammal that are accomplished by administering doses of a compound that is a selective partial A2A receptor agonist with a short duration of action, in particular regadenoson, useful for, among other indications, myocardial imaging and coronary vasodilation, and determining areas of insufficient blood flow.
    Type: Grant
    Filed: May 4, 2009
    Date of Patent: December 6, 2011
    Assignee: Gilead Sciences, Inc.
    Inventors: Luiz Belardinelli, Brent K. Blackburn, Zhenhai Gao
  • METHOD OF TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20110184002
    Abstract: The invention is related to methods of preventing and treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method.
    Type: Application
    Filed: August 10, 2010
    Publication date: July 28, 2011
    Applicant: Gilead Sciences, Inc.
    Inventors: Luiz Belardinelli, Dewan Zeng, Hongyan Zhong
  • METHOD OF TREATING ATRIAL FIBRILLATION
    Publication number: 20110183990
    Abstract: The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.
    Type: Application
    Filed: December 20, 2010
    Publication date: July 28, 2011
    Inventors: Charles Antzelevitch, Luiz Belardinelli, Alexander Burashnikov, John Shryock, Dewan Zeng
  • N-PYRAZOLE A2A RECEPTOR AGONISTS
    Publication number: 20110144320
    Abstract: 2-adenosine N-pyrazole compounds having the following formula: and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
    Type: Application
    Filed: December 14, 2010
    Publication date: June 16, 2011
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle, Luiz Belardinelli
  • RANOLAZINE FOR THE TREATMENT OF CNS DISORDERS
    Publication number: 20100292217
    Abstract: The present invention relates to a method for CNS disorders such as epilepsy and migraine comprising the administration of a therapeutically effective amount of ranolazine.
    Type: Application
    Filed: May 13, 2010
    Publication date: November 18, 2010
    Applicant: Gilead Palo Alto, Inc.
    Inventors: Luiz Belardinelli, Alfred George, Kristopher Kahlig, Sridharan Rajamani
  • MYOCARDIAL PERFUSION IMAGING METHOD
    Publication number: 20100272645
    Abstract: A myocardial imaging method that is accomplished by administering one or more adenosine A2A adenosine receptor agonist to a human undergoing myocardial imaging.
    Type: Application
    Filed: January 27, 2010
    Publication date: October 28, 2010
    Inventor: Luiz Belardinelli
  • Method of treating hepatic disease using Aadenosine receptor antagonists
    Patent number: 7795268
    Abstract: The invention is related to methods of treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: September 14, 2010
    Assignee: Gilead Palo Alto, Inc.
    Inventors: Dewan Zeng, Hongyan Zhong, Luiz Belardinelli
  • MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS
    Publication number: 20100183503
    Abstract: A myocardial imaging method that is accomplished by administering one or more adenosine A2A adenosine receptor agonist to a human undergoing myocardial imaging as well as pharmaceutical compositions comprising at least one A2a receptor agonist, at least one liquid carrier, and at least one co-solvent.
    Type: Application
    Filed: March 29, 2010
    Publication date: July 22, 2010
    Inventors: Luiz Belardinelli, Mitchell Rosner
  • USE OF A2A ADENOSINE RECEPTOR AGONISTS
    Publication number: 20100158797
    Abstract: Myocardial imaging methods that are accomplished by administering doses of a pharmaceutical composition including regadenoson—an adenosine A2A receptor agonist—to a human undergoing myocardial imaging in an amount sufficient to achieve at least a minimal increase in average coronary peak flow velocity.
    Type: Application
    Filed: December 14, 2009
    Publication date: June 24, 2010
    Inventors: Toufigh Gordi, Ann Walls Olmsted, Hsiao Dee Lieu, Luiz Belardinelli
  • N-PYRAZOLE A2A RECEPTOR AGONISTS
    Publication number: 20100160620
    Abstract: 2-adenosine N-pyrazole compounds having the following formula: and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
    Type: Application
    Filed: December 14, 2009
    Publication date: June 24, 2010
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle, Luiz Belardinelli
  • CO-ADMINISTRATION OF RANOLAZINE AND CARDIAC GLYCOSIDES
    Publication number: 20100130436
    Abstract: The present invention relates to a method for reducing the toxicity of cardiac glycosides comprising the coadministration of a therapeutically effective amount of cardiac glycoside and a therapeutically effective amount ranolazine. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.
    Type: Application
    Filed: November 24, 2009
    Publication date: May 27, 2010
    Applicant: Gilead Palo Alto, Inc.
    Inventors: Luiz Belardinelli, Kirsten Hoyer, John Shryock
  • METHOD FOR ENHANCING INSULIN SECRETION
    Publication number: 20100105695
    Abstract: The invention is directed to methods for enhancing endogenous insulin levels in a patient in need thereof which method comprises administering to the patient an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine. It is also directed to methods of treatment comprising racemic ranolazine or the R- or S-enantiomer of ranolazine for enhancing endogenous insulin levels in a patient in need thereof. It is also directed to a composition comprising an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine and at least one anti-diabetic agent.
    Type: Application
    Filed: January 4, 2010
    Publication date: April 29, 2010
    Applicant: Gilead Palo Alto, Inc.
    Inventors: Arvinder Dhalla, Luiz Belardinelli, John Shryock, Kwan Leung, Dewan Zeng
  • METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20100105706
    Abstract: The present invention relates to methods of preventing airway remodeling using A2B adenosine receptor antagonists. This invention finds utility in the treatment and prevention of asthma, COPD, pulmonary fibrosis, emphysema, and other pulmonary diseases. The invention also relates to pharmaceutical compositions for use in the method.
    Type: Application
    Filed: October 26, 2009
    Publication date: April 29, 2010
    Applicant: Gilead Palo Alto, Inc.
    Inventors: Dewan Zeng, Michael R. Blackburn, Luiz Belardinelli